Choate Investment Advisors grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 3.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 10,052 shares of the biopharmaceutical company’s stock after acquiring an additional 358 shares during the period. Choate Investment Advisors’ holdings in […]
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) insider Johanna Mercier sold 8,242 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the completion of the transaction, the insider now owns 82,729 shares in the company, […]
Whittier Trust Co. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,239 shares of the biopharmaceutical company’s stock after selling 634 shares during the quarter. Whittier Trust Co.’s […]
Brighton Jones LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,349 shares of the biopharmaceutical company’s stock after acquiring an additional 301 […]
WESPAC Advisors LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,928 shares of the biopharmaceutical company’s stock, valued at approximately $219,000. A number of other institutional investors have […]